Supriya Lifescience Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 19,160,585 (75%) | — | ₹52,500 Cr |
| NII (HNI) | — | 3,832,116 (15%) | — | ₹10,500 Cr |
| Retail | — | 2,554,744 (10%) | — | ₹7,000 Cr |
| Σ Total | — | 25,547,445 (100%) | — | ₹700,000 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 54 | ₹14,796 |
| Retail (Max) | 13 | 702 | ₹192,348 |
| S-HNI (Min) | 14 | 756 | ₹207,144 |
| B-HNI (Min) | 67 | 3,618 | ₹991,332 |
Financial Statements Amount in Crore
| Metric | 30-Sep-21 | 31-Mar-21 | 31-Mar-20 |
|---|---|---|---|
| Revenue | 230 | 396 | 323 |
| Profit After Tax | 66 | 124 | 73 |
| Total Assets | 504 | 446 | 336 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 Funding capital expenditure requirements of the Company; – 92.30
- 2 Repayment and/ or pre-payment, in full or part, of certain borrowings availed by the Company – 60.00
- 3 General corporate purposes. – 35.95
Company Overview
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume.
In Fiscal 2021, the company's products were exported to 86 countries to 1,296 customers including 346 distributors. The company has API business in Europe, Latin America, Asia, and North America.
Supriya Lifescience has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company's manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to API products being exported to the relevant jurisdictions by the company.